Author of

• 11595

  +

  P2.07 - Poster Session 2 - Surgery (ID 190)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Surgery
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11609

    +

    P2.07-014 - Intrapleural Perfusion Hyperthermic Chemotherapy in Malignant Pleural Effusion and Pleural Seeding (ID 2580)

    09:30 - 09:30  |  Author(s): D. Noh
    • Abstract

    Background
    Malignant pleural effusion or pleural seeding is detected in advanced non-small cell lung cancer (NSCLC) patients, and they are generally associated with poor prognosis. Systemic chemotherapy is the mainstay modality in these patients. However, it is not enough to improve the survival. Intrapleural perfusion hyperthermic chemotherapy (IPHC) provides direct effect to pleural seeding cancer cells. This study attempted to evaluate the efficacy and safety of IPHC.

    Methods
    From 2003 to 2012, 41 patients who underwent IPHC for malignant pleural effusion or pleural seeding for NSCLC in our institute. The IPHC was performed with cisplatin (dose:150-200mg/m[2]) for 90 minutes after resection of primary tumor. Efficacy was determined by computed tomography and Positron Emission Tomographic (PET) standardized uptake value (SUV) postoperatively.

    Results
    The IPHC group consisted of 25 males and 16 females. The mean age was 60.98±9.80 year ranging from 33 to 78. Preoperative pleural mean SUV was 1.46±1.88 (R: 0-6) and postoperative pleural mean SUV was 1.58±1.72 (R: 0-5) (p= 0.933). Sixteen patients were received adjuvant systemic chemotherapy. The 2-year and 5-year survival rate were 82.1% and 44.9%, respectively. Major post-IPHC complications are acute renal insufficiency (n=4, 9.76%) and arrhythmia (n=2, 4.88%). There were no difference in sex, age, adjuvant systemic chemotherapy, tumor size, nodal statues between the patients who survived more than 2 years and less than 2 years. There was no difference in SUV of preoperative main mass and pleura between the patients who survived more than 2 years and less than 2 years. However, the SUV of postoperative pleura in the patients who survived more than 2 years (SUV: 2.92±1.98) was less than that of the patients who survived less than 2 years (SUV: 1.16±1.45) (p=0.031).

    Conclusion
    IPHC would be safety procedure for malignant pleural effusion or pleural seeding. IPHC may provide better survival compared with the systemic chemotherapy only in the highly selected patients. Low post-IPHC SUV uptake would be provide longer survivor.